AbbVie’s (ABBV) “Outperform” Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of AbbVie (NYSE:ABBV) in a research note released on Tuesday morning,Benzinga reports. Royal Bank Of Canada currently has a $280.00 price objective on the stock.

Several other equities research analysts have also commented on ABBV. Leerink Partners boosted their price target on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Bank of America restated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Canaccord Genuity Group raised their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. BNP Paribas Exane raised their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Finally, Citigroup lifted their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Price Performance

Shares of ABBV stock opened at $283.07 on Tuesday. The business’s fifty day moving average price is $261.95 and its 200 day moving average price is $238.90. The firm has a market capitalization of $500.13 billion, a PE ratio of 26.08, a P/E/G ratio of 1.29 and a beta of 0.24. AbbVie has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm posted $2.97 EPS. The business’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts expect that AbbVie will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s payout ratio is presently 195.48%.

Insider Activity

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Corient Private Wealth LP acquired a new stake in AbbVie during the 2nd quarter valued at $559,736,000. Legal & General Group Plc purchased a new stake in AbbVie during the 2nd quarter worth about $2,905,952,000. Jupiter Topco LLC purchased a new stake in AbbVie during the 2nd quarter worth about $1,560,354,000. Diamant Asset Management Inc. raised its stake in AbbVie by 21,649.0% in the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after purchasing an additional 3,654,351 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in AbbVie in the 2nd quarter valued at about $817,473,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 data for a subcutaneous version of SKYRIZI showed meaningful clinical and endoscopic benefits in adults with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient induction option and strengthen confidence that SKYRIZI can help offset the loss of Humira revenue. Abbvie’s Crohn’s Disease Drug Skyrizi Shows More Positive Results
• Positive Sentiment: Analyst sentiment remains constructive. Royal Bank of Canada reaffirmed an Outperform rating, while Erste Group raised its 2027 EPS estimate to $16.34 from $16.19 and maintained a Buy rating. These views reinforce the argument that AbbVie’s newer drugs are driving sustainable post-Humira growth. Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie
• Positive Sentiment: Investors are also watching early clinical work on oral candidate ABBV-1042. The study remains at an early stage and is being conducted in healthy participants, but positive progress could add value to AbbVie’s long-term pipeline. AbbVie’s ABBV-1042 Trial Update
• Neutral Sentiment: AbbVie’s third-quarter earnings report is scheduled for October 30. Investors will be looking for confirmation that SKYRIZI and RINVOQ growth is more than compensating for Humira’s decline; the company’s current guidance calls for third-quarter EPS of $3.84 to $3.88. AbbVie’s Q3 2026 Earnings: What to Expect
• Neutral Sentiment: Heavy call-option activity and a broad healthcare-sector rally indicate increased investor interest, but options positioning is not a fundamental catalyst by itself. Lower Treasury yields may also be supporting defensive healthcare shares.
• Negative Sentiment: Some investors remain concerned that AbbVie’s valuation is demanding after its rally. Comparisons with Sanofi have highlighted Sanofi’s stronger outlook and valuation, potentially limiting further upside. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.